Bibliographical noteFunding Information:
This project, ZikaPLAN is funded by the European Union?s Horizon 2020 research and innovation programme under Grant Agreement No. h2020 health 734584. Some authors have received additional research funding. The Microencephaly Epidemic Research Group (MERG) has received additional funding from Wellcome Trust UK, Department for International Development UK, Medical Research Council UK, the Brazilian funding through CNPq, Secretaria de Vigil?ncia de Sa?de (SVS), and Funda??o do Amparo a Ci?ncia e Tecnologia (FACEPE). LT is supported by a Wellcome Trust fellowship [205228/Z/16/Z]. The Latin American Congenital Malformations Network (ReLAMC) group has received additional Brazilian funding through DECIT, CNPq (440614/2016-3), and CAPES (88887.130724/2016-00, 88887.130724/2016-00) We acknowledge the Department of Epidemiology and Global Health of Ume? University, Sweden for hosting the ZikaPLAN consortium, and express our appreciation for the extremely professional and always friendly project office. We thank all our consortium members and their institutions, and we are thankful to many other institutional staff members (all the administrators and financial managers) who participated and supported the implementation of the ZikaPLAN project in different capacities. Our special thanks to Prof Laura Rodrigues from the London School of Hygiene & Tropical Medicine, UK, for her pioneering spirit, foresight and epidemiological acumen in setting up the Microencephaly Epidemic Research Group (MERG) together with many ZikaPLAN colleagues in Brazil very early on in the Zika epidemic even before EU funding was available. We would like to thank Koren Wolman-Tardy and Margaux Luciani for their professional approach to developing videos, organizing the dissemination events, and coordinating the ZikaPLAN newsletters and website. We are grateful to our Scientific Advisory Board members (Duane Gubler, James Sejvar, Herman Goossens) and Ethics Advisory Committee member (Anna Durbin) for their timely support and guidance at various stages of the project. We deeply appreciate our collaborative work with ZIKAction (Grant Agreement No. 734857) and ZIKAlliance (Grant Agreement No. 734548) which allowed us in collectively advancing common efforts and strengthening the research output as one voice creating larger impact thereby setting an example of collaboration and data sharing.
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
- congenital Zika syndrome
- birth defect
- epidemic preparedness
- research capacity building
- European Commission
- Guillain-Barré Syndrome
- Global Health
- Zika Virus
- Infectious Disease Transmission, Vertical
- Zika Virus Infection - complications - epidemiology - prevention & control
- Zika Virus Infection/complications